Oncogenic signaling: new insights and controversies from chronic myeloid leukemia

Chronic myeloid leukemia (CML), which is caused by the BCR–ABL fusion tyrosine kinase, is one of the most intensively studied human cancers. ABL kinase inhibitors have been spectacularly successful in treating CML, but disease persistence and acquired drug resistance can prevent eradication and cure...

Descripción completa

Detalles Bibliográficos
Autor principal: Van Etten, Richard A.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2007
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2137897/
https://www.ncbi.nlm.nih.gov/pubmed/17353369
http://dx.doi.org/10.1084/jem.20062335
_version_ 1782143437967982592
author Van Etten, Richard A.
author_facet Van Etten, Richard A.
author_sort Van Etten, Richard A.
collection PubMed
description Chronic myeloid leukemia (CML), which is caused by the BCR–ABL fusion tyrosine kinase, is one of the most intensively studied human cancers. ABL kinase inhibitors have been spectacularly successful in treating CML, but disease persistence and acquired drug resistance can prevent eradication and cure of the leukemia. The development of better therapies will depend on a full understanding of signaling pathways in CML, facilitated by model studies using mutant mice.
format Text
id pubmed-2137897
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21378972007-12-13 Oncogenic signaling: new insights and controversies from chronic myeloid leukemia Van Etten, Richard A. J Exp Med Commentaries Chronic myeloid leukemia (CML), which is caused by the BCR–ABL fusion tyrosine kinase, is one of the most intensively studied human cancers. ABL kinase inhibitors have been spectacularly successful in treating CML, but disease persistence and acquired drug resistance can prevent eradication and cure of the leukemia. The development of better therapies will depend on a full understanding of signaling pathways in CML, facilitated by model studies using mutant mice. The Rockefeller University Press 2007-03-19 /pmc/articles/PMC2137897/ /pubmed/17353369 http://dx.doi.org/10.1084/jem.20062335 Text en Copyright © 2007, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Commentaries
Van Etten, Richard A.
Oncogenic signaling: new insights and controversies from chronic myeloid leukemia
title Oncogenic signaling: new insights and controversies from chronic myeloid leukemia
title_full Oncogenic signaling: new insights and controversies from chronic myeloid leukemia
title_fullStr Oncogenic signaling: new insights and controversies from chronic myeloid leukemia
title_full_unstemmed Oncogenic signaling: new insights and controversies from chronic myeloid leukemia
title_short Oncogenic signaling: new insights and controversies from chronic myeloid leukemia
title_sort oncogenic signaling: new insights and controversies from chronic myeloid leukemia
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2137897/
https://www.ncbi.nlm.nih.gov/pubmed/17353369
http://dx.doi.org/10.1084/jem.20062335
work_keys_str_mv AT vanettenricharda oncogenicsignalingnewinsightsandcontroversiesfromchronicmyeloidleukemia

Ejemplares similares